GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » Beneish M-Score

Puma Biotechnology (Puma Biotechnology) Beneish M-Score : -2.49 (As of Apr. 29, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.49 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Puma Biotechnology's Beneish M-Score or its related term are showing as below:

PBYI' s Beneish M-Score Range Over the Past 10 Years
Min: -3.52   Med: -2.7   Max: 2.39
Current: -2.49

During the past 13 years, the highest Beneish M-Score of Puma Biotechnology was 2.39. The lowest was -3.52. And the median was -2.70.


Puma Biotechnology Beneish M-Score Historical Data

The historical data trend for Puma Biotechnology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology Beneish M-Score Chart

Puma Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.52 -3.18 -2.90 -1.33 -2.49

Puma Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.33 -1.96 -2.82 -2.68 -2.49

Competitive Comparison of Puma Biotechnology's Beneish M-Score

For the Biotechnology subindustry, Puma Biotechnology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Beneish M-Score falls into.



Puma Biotechnology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Puma Biotechnology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1101+0.528 * 1.0333+0.404 * 0.8407+0.892 * 1.0334+0.115 * 0.7708
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9566+4.679 * -0.024084-0.327 * 0.8834
=-2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $48.5 Mil.
Revenue was 72.178 + 56.116 + 54.568 + 52.775 = $235.6 Mil.
Gross Profit was 47.855 + 42.832 + 42.711 + 39.557 = $173.0 Mil.
Total Current Assets was $156.2 Mil.
Total Assets was $230.5 Mil.
Property, Plant and Equipment(Net PPE) was $8.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.5 Mil.
Selling, General, & Admin. Expense(SGA) was $88.9 Mil.
Total Current Liabilities was $99.4 Mil.
Long-Term Debt & Capital Lease Obligation was $72.7 Mil.
Net Income was 12.268 + 5.796 + 2.126 + 1.401 = $21.6 Mil.
Non Operating Income was 0.641 + -0.551 + 0.086 + -0.042 = $0.1 Mil.
Cash Flow from Operations was 10.455 + 10.615 + 3.296 + 2.643 = $27.0 Mil.
Total Receivables was $42.3 Mil.
Revenue was 65.675 + 57.102 + 59.518 + 45.736 = $228.0 Mil.
Gross Profit was 48.839 + 44.607 + 44.6 + 34.892 = $172.9 Mil.
Total Current Assets was $134.3 Mil.
Total Assets was $222.1 Mil.
Property, Plant and Equipment(Net PPE) was $12.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.8 Mil.
Selling, General, & Admin. Expense(SGA) was $90.0 Mil.
Total Current Liabilities was $77.5 Mil.
Long-Term Debt & Capital Lease Obligation was $110.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(48.489 / 235.637) / (42.27 / 228.031)
=0.205778 / 0.18537
=1.1101

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(172.938 / 228.031) / (172.955 / 235.637)
=0.758397 / 0.733989
=1.0333

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (156.185 + 8.647) / 230.528) / (1 - (134.281 + 12.508) / 222.059)
=0.284981 / 0.338964
=0.8407

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=235.637 / 228.031
=1.0334

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.84 / (9.84 + 12.508)) / (11.519 / (11.519 + 8.647))
=0.440308 / 0.571209
=0.7708

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(88.941 / 235.637) / (89.978 / 228.031)
=0.377449 / 0.394587
=0.9566

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((72.693 + 99.382) / 230.528) / ((110.141 + 77.484) / 222.059)
=0.746439 / 0.844933
=0.8834

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(21.591 - 0.134 - 27.009) / 230.528
=-0.024084

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Puma Biotechnology has a M-score of -2.49 suggests that the company is unlikely to be a manipulator.


Puma Biotechnology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology (Puma Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Executives
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139